A How-to Guide for Trial Summary 3.1.3
|
|
|
- Milton Harrell
- 9 years ago
- Views:
Transcription
1 A How-to Guide for Trial Summary Nicola Tambascia & Anita Eisberg Accovion GmbH PhUSE SDE Frankfurt 2014 A How-to Guide for Trial Summary 3.1.3, May 6 th 2014, PhUSE SDE Frankfurt 1
2 Agenda CDISC SDTM Trial Summary domain (TS) General introduction What s new for Trial Summary in SDTM IG (SDTM 1.3) How & where to find the information for TS requested in SDTM IG A How-to Guide for Trial Summary 3.1.3, May 6 th 2014, PhUSE SDE Frankfurt 2
3 Trial Summary general introduction Trial Summary is used to record basic information about the trial, such as trial phase, protocol title and design objectives The Trial Summary Information Domain (TS) contains one record for each trial summary characteristic This is not subject-level data example from SDTM IG section A How-to Guide for Trial Summary 3.1.3, May 6 th 2014, PhUSE SDE Frankfurt 3
4 What s new for Trial Summary in SDTM IG Row STUDYID DOMAIN TSSEQ TSPARMCD TSPARM TSVAL TSVALNF TSVALCD TSVCDREF TSVCDVER 1 ABC TS 1 AGEMIN 2 ABC TS 1 AGEMAX Planned Minimum Age of Subjects Planned Maximum Age of Subjects 3 ABC TS 1 AGEU Age Unit YEARS 4 ABC TS 1 COMPTRT 5 ABC TS 1 DESIGN Comparative Treatment Name Description of Trial Design 6 ABC TS 1 INDIC Trial Indication 18 P18Y ISO P64Y ISO 8601 PLACEBO Parellel Tonic-Clonic Generalized Epilepsy Disease SNOMED (Disorder) Structure in SDTM IG ABC TS 1 LENGTH Trial Length P14W ISO ABC TS 1 PLANSUB 9 ABC TS 1 PLANEVAL 10 ABC TS 1 SEXPOP Planned Number of Subjects Planned Number of Evaluable Subjects Sex of Participants BOTH C49636 CDISC ABC TS 1 RANDOM Trial is Randomized Y C49488 CDISC ABC TS 1 TBLIND Trial Blinding Schema DOUBLE BLIND C15228 CDISC ABC TS 1 TCNTRL Type of Control PLACEBO C49648 CDISC And many more new parameters added in SDTM IG A How-to Guide for Trial Summary 3.1.3, May 6 th 2014, PhUSE SDE Frankfurt 4
5 Extended list of parameters SDTM IG SDTM IG Recommended minimum set: TITLE, INDIC, TCNTRL, RANDOM, TRT, COMPTRT (when applicable), AGESPAN, AGEMIN, AGEMAX, AGEU, SEXPOP, PLANSUB, OBJPRIM, OBJSEC Optional: ADDON, DOSE, DOSFRQ, DOSU, LENGTH, ROUTE, SPONSOR, STOPRULE, TBLIND, TDIGRP, TINDTP, TPHASE from SDTM IG section Required: ADDON, AGEMIN, AGEMAX, LENGTH, PLANSUB, RANDOM, SEXPOP, STOPRULE, TBLIND, TCNTRL, TITLE, TPHASE, TTYPE, OBJPRIM, SPONSOR, REGID, OUTMSPRI, FCNTRY, ADAPT, DCUTDTC, DCUTDESC, NARMS, STYPE, SSTDTC, SENDTC, ACTSUB, HLTSUBJI Conditionally required: TDIGRP, TINDTP, CURTRT, TRT, RANDQT, PCLAS, INTMODEL, INTTYPE If applicable: OBJSEC, COMPTRT, INDIC, STRATFCT, OUTMSSEC, OUTMSEXP, SDMDUR, CRMDUR from SDTM IG Appendix C3 A How-to Guide for Trial Summary 3.1.3, May 6 th 2014, PhUSE SDE Frankfurt 5
6 Changes from SDTM IG to Additional variables Code list variables Null flavor Higher demand for controlled terminology from SDTM IG Appendix C3 A How-to Guide for Trial Summary 3.1.3, May 6 th 2014, PhUSE SDE Frankfurt 6
7 New: Code List Variables Variables TSVALCD, TSVCDREF, TSVCDVER TSVALCD Code of parameter value TSVCDREF Name of reference terminology TSVCDVER Version of the reference terminology Should be filled for all parameters where controlled terminology is required Examples are given in the SDTM IG 3.1.3, e.g. TSPARMCD TSPARM TSVAL TSVALNF TSVALCD TSVCDREF TSVCDVER RANDOM Trial is Randomized Y C49488 CDISC A How-to Guide for Trial Summary 3.1.3, May 6 th 2014, PhUSE SDE Frankfurt 7
8 New: Null Flavor Variable Variable TSVALNF (fill TSVCDREF with ISO 21090) To be filled, if no value for TSVAL is available Uses ISO null flavor terminology, e.g. NI No information PINF Positive infinity, e.g. UNK Unknown NA Not applicable TSPARMCD TSPARM TSVAL TSVALNF TSVALCD TSVCDREF TSVCDVER Planned AGEMAX Maximum Age of Subjects Complete list available in SDTM IG section PINF ISO A How-to Guide for Trial Summary 3.1.3, May 6 th 2014, PhUSE SDE Frankfurt 8
9 Higher Demand for Controlled Terminology Very few parameters without controlled terminology: Text from study protocol: TITLE, OBJPRIM, OBJSEC, OUTMSPRI, OUTMSSEC, OUTMSEXP, STOPRULE, DCUTDESC Numbers: PLANSUB, ACTSUB, NARMS, RANDQT Variable names: STRATFCT Everything else is controlled. A How-to Guide for Trial Summary 3.1.3, May 6 th 2014, PhUSE SDE Frankfurt 9
10 How & where to find the information for TS requested in SDTM IG ISO 8601 & ISO alpha-3 CDISC controlled terminology Some of the code lists named in the SDTM IG might not be easy to access or even unavailable, e.g. UNII, SRS Preferred Substance Name NDF-RT DUNS SNOMED A How-to Guide for Trial Summary 3.1.3, May 6 th 2014, PhUSE SDE Frankfurt 10
11 Example usage of CDISC CT Source: nologyresources/cdisc TSPARMCD TSPARM TSVAL TSVALNF TSVALCD TSVCDREF TSVCDVER RANDOM Trial is Randomized Y C49488 CDISC A How-to Guide for Trial Summary 3.1.3, May 6 th 2014, PhUSE SDE Frankfurt 11
12 List of controlled terms from ISO & CDISC CT ISO 8601 Dates & duration for: AGEMAX, AGEMIN, LENGTH, DCUTDTC, SSTDTC, SENDTC, SDMDUR, CRMDUR ISO alpha-3 Country codes for FCNTRY No Yes Response Sex of Participants Trial Blinding Schema Control Type Trial Indication Type Trial Phase Trial Type Intervention Model Study Type Intervention Type A How-to Guide for Trial Summary 3.1.3, May 6 th 2014, PhUSE SDE Frankfurt 12
13 UNII, SRS Preferred Substance Name FDA Substance Registration System Unique Ingredient Identifier To be used for: TRT Investigational Therapy or Treatment CURTRT Current Therapy or Treatment COMPTRT Comparative Treatment Name Source: Use UNII for TSVALCD Use Preferred Substance Name for TSVAL A How-to Guide for Trial Summary 3.1.3, May 6 th 2014, PhUSE SDE Frankfurt 13
14 UNII, SRS Preferred Substance Name TSPARMCD TSPARM TSVAL TSVALNF TSVALCD TSVCDREF TSVCDVER TRT Investigational Therapy or Treatment METFORMIN 9100L32L2N UNII A How-to Guide for Trial Summary 3.1.3, May 6 th 2014, PhUSE SDE Frankfurt 14
15 NDF-RT Veterans Affairs National Drug File Reference Terminology To be used for PCLAS - Pharmacological Class Source: ductlabeling/ucm htm : Downloadable ZIP file FDA Pharmacologic Classes also contains UNII A How-to Guide for Trial Summary 3.1.3, May 6 th 2014, PhUSE SDE Frankfurt 15
16 NDF-RT TSPARMCD TSPARM TSVAL TSVALNF TSVALCD TSVCDREF TSVCDVER PCLAS Pharmacological Class of Investigational Therapy Biguanide N NDF-RT A How-to Guide for Trial Summary 3.1.3, May 6 th 2014, PhUSE SDE Frankfurt 16
17 DUNS Data Universal Numbering System by Dun and Bradstreet To be used for: Source: SPONSOR Clinical Study Sponsor (German) (English) A How-to Guide for Trial Summary 3.1.3, May 6 th 2014, PhUSE SDE Frankfurt 17
18 DUNS A How-to Guide for Trial Summary 3.1.3, May 6 th 2014, PhUSE SDE Frankfurt 18
19 DUNS TSPARMCD TSPARM TSVAL TSVALNF TSVALCD TSVCDREF TSVCDVER SPONSOR Clinical Study Sponsor MERCK Kommandit gesellschaft auf Aktien DUNS A How-to Guide for Trial Summary 3.1.3, May 6 th 2014, PhUSE SDE Frankfurt 19
20 SNOMED Systematized Nomenclature of Medicine To be used for INDIC Trial Indication TDIGRP Diagnosis Group Problem: Not licensed in many companies, especially outside of the U.S. Proposal: Use terms as described in protocol TSPARMCD TSPARM TSVAL TSVALNF TSVALCD TSVCDREF TSVCDVER INDIC TDIGRP Trial Indication Diagnosis Group Tonic-Clonic Epilepsy (Disorder) Subjects with type 2 diabetes mellitus SNOMED SNOMED A How-to Guide for Trial Summary 3.1.3, May 6 th 2014, PhUSE SDE Frankfurt 20
21 REGID: CT.GOV / EUDRACT CT.GOV Source: TSPARMCD TSPARM TSVAL TSVALNF TSVALCD TSVCDREF TSVCDVER REGID Registry Identifier NCT NCT CT.GOV REGID Registry Identifier XYZ1234 XYZ1234 EUDRACT EudraCT number often found in protocol A How-to Guide for Trial Summary 3.1.3, May 6 th 2014, PhUSE SDE Frankfurt 21
22 Questions? Nicola Tambascia Senior Statistical Programmer Accovion GmbH Helfmann-Park 10 D Eschborn, Germany Tel Anita Eisberg Principal Statistical Programmer Accovion GmbH Software Center 3 D Marburg, Germany Tel [email protected] A How-to Guide for Trial Summary 3.1.3, May 6 th 2014, PhUSE SDE Frankfurt 22
Implementation Guide for Study Design Structured. Document. FDA Guidance for Human Clinical Trials
Implementation Guide for Study Design Structured Document FDA Guidance for Human Clinical Trials i Table of Contents 1 Acknowledgements... 1 2 Introduction... 1 2.1 Audience... 1 2.2 Approach... 1 2.3
Trials and Tribulations of SDTM Trial Design
PharmaSUG 2011 - Paper CD13 Trials and Tribulations of SDTM Trial Design Fred Wood, Octagon Research Solutions, Wayne, PA Mary Lenzen, Octagon Research Solutions, Wayne, PA ABSTRACT An increasing number
TEMPLATE DATA MANAGEMENT PLAN
TEMPLATE DATA MANAGEMENT PLAN ICRIN (QM sub group) Version: XX Date: XXXXXXX Page 1 of 6 1.0 Document Ownership The Data Management Plan (DMP) will be initiated and subsequently owned by the Data Manager
Pharmaceutical Applications
Integrated Summary of Safety and Efficacy Programming for Studies Using Electronic Data Capture Changhong Shi, Merck & Co., Inc., Rahway, NJ Qing Xue, Merck & Co., Inc., Rahway, NJ ABSTRACT The Integrated
PHARMACY AND POISONS ORDINANCE (Cap. 138) APPLICATION FOR A CLINICAL TRIAL/MEDICINAL TEST CERTIFICATE
PHARMACY AND POISONS ORDINANCE (Cap. 138) APPLICATION FOR A CLINICAL TRIAL/MEDICINAL TEST CERTIFICATE PART A: TRIAL INFORMATION A1. Title of Clinical Trial (as stated in proposed Protocol) Protocol No.
Rationale and vision for E2E data standards: the need for a MDR
E2E data standards, the need for a new generation of metadata repositories Isabelle de Zegher, PAREXEL Informatics, Belgium Alan Cantrell, PAREXEL, United Kingdom Julie James, PAREXEL Informatics, United
PharmaSUG 2015 - Paper DS02
PharmaSUG 05 - Paper DS0 SDTM TE, T, and SE Domains: Demystifying the Development of SE Kristin Kelly, ccenture ccelerated R&D Services, erwyn, P Fred Wood, ccenture ccelerated R&D Services, erwyn, P Jerry
The ADaM Solutions to Non-endpoints Analyses
The ADaM Solutions to Non-endpoints Analyses ABSTRACT Chengxin Li, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA There always exist some analyses for non endpoints in the study. These
Business & Decision Life Sciences What s new in ADaM
Business & Decision Life Sciences What s new in ADaM Gavin Winpenny 23 rd June 2015 Agenda What s happening CDISC and Regulatory Submission Landscape ADaM Implementation Guide ADaM Data Structures for
Managing Data and Providing Competitive Insights from Clinical Trials Using BizInt Smart Charts
Managing Data and Providing Competitive Insights from Clinical Trials Using BizInt Smart Charts Pharma-Bio-Med 2011 - Venice, Italy 21 Nov 2011 Diane Webb, President, BizInt Solutions Jennifer Friend-Huizer,
Copyright 2012, SAS Institute Inc. All rights reserved. VISUALIZATION OF STANDARD TLFS FOR CLINICAL TRIAL DATA ANALYSIS
VISUALIZATION OF STANDARD TLFS FOR CLINICAL TRIAL DATA ANALYSIS WENJUN BAO AND JASON CHEN JMP, SAS INC. PHUSE, SHANGHAI, NOV 28, 2014 OUTLINES: CDISC Standard SDTM ADaM Interactive Standardized TLFs Tables
SDTM AND ADaM: HANDS-ON SOLUTIONS
SDTM AND ADaM: HANDS-ON SOLUTIONS CDISC French Speaking User Group Paris, France 17 February 2012 Joris De Bondt, Head Data Standards & Process Improvements Tineke Callant, Senior Biostatistical Analyst
Einführung in die CDISC Standards CDISC Standards around the World. Bron Kisler (CDISC) & Andrea Rauch DVMD Tagung 11.-14.
Einführung in die CDISC Standards CDISC Standards around the World Bron Kisler (CDISC) & Andrea Rauch DVMD Tagung 11.-14. März 2015 1 Outline Overview of CDISC Therapeutic Area Standards SHARE Metadata
ABSTRACT INTRODUCTION PATIENT PROFILES SESUG 2012. Paper PH-07
Paper PH-07 Developing a Complete Picture of Patient Safety in Clinical Trials Richard C. Zink, JMP Life Sciences, SAS Institute, Cary, NC, United States Russell D. Wolfinger, JMP Life Sciences, SAS Institute,
Josephine Silvestre, RN, MSN The University of Chicago Medical Center. October 13, 2007
Josephine Silvestre, RN, MSN The University of Chicago Medical Center October 13, 2007 A study in which people participate as volunteers. A clinical trial is conducted to develop potential new treatments
PK IN DRUG DEVELOPMENT. CDISC management of PK data. Matteo Rossini Milan, 9 February 2010
Matteo Rossini Milan, 9 February 2010 Introduction to CDISC CDISC: Clinical Data Interchange Standards Consortium CDISC is a global, open, multidisciplinary, non-profit organization that has established
Effect of liraglutide on body weight in overweight or obese subjects with type 2 diabetes: SCALE - Diabetes
Effect of liraglutide on body weight in overweight or obese subjects with type 2 diabetes: SCALE - Diabetes This trial is conducted in Africa, Asia, Europe and the United States of America (USA). The aim
The Main Challenges around IDMP 1 and Ways to Solve Them. Article by Dieter Schlaps, IT Consulting Life Science, Wessobrunn, Germany
The Main Challenges around IDMP 1 and Ways to Solve Them Article by Dieter Schlaps, IT Consulting Life Science, Wessobrunn, Germany Abstract: As of 1 July 2016, pharmaceutical companies which develop and
Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes
Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes U.S. Department of Health and Human Services Food and Drug Administration Center
ehr Sharable Data Vicky Fung Senior Health Informatician ehr Information Standards Office
ehr Sharable Data Vicky Fung Senior Health Informatician ehr Information Standards Office ehr - Vision DH HA epr Private Private Hospit als Hospitals EHR Repository Access Portal CMS onramp PPP Clinics
Singapore Clinical Trials Register. Foo Yang Tong Director Clinical Trials Branch Health Products Regulation Group HEALTH SCIENCES AUTHORITY
Singapore Clinical Trials Register Foo Yang Tong Director Clinical Trials Branch Health Products Regulation Group HEALTH SCIENCES AUTHORITY Clinical Trial Register Global Trend EMA: EU Clinical Trials
PhUSE Annual Meeting, London 2014
PhUSE Annual Meeting, London 2014 Metadata, Study data standards, Master data, terminology, interoperability: Key concepts underlying compliance to FDA guidance on electronic submission Isabelle de Zegher,
Metadata Submission Guidelines Appendix to the Study Data Tabulation Model Implementation Guide
Metadata Submission Guidelines Appendix to the Study Data Tabulation Model Implementation Guide Prepared by the CDISC SDS Metadata Team Notes to Readers This is Version 0.9 of the Metadata Submissions
Overview of CDISC Implementation at PMDA. Yuki Ando Senior Scientist for Biostatistics Pharmaceuticals and Medical Devices Agency (PMDA)
Overview of CDISC Implementation at PMDA Yuki Ando Senior Scientist for Biostatistics Pharmaceuticals and Medical Devices Agency (PMDA) CDISC 2012 Outline Introduction Update of PMDA activity CDISC implementation
CDISC and Clinical Research Standards in the LHS
CDISC and Clinical Research Standards in the LHS Learning Health System in Europe 24 September 2015, Brussels Rebecca D. Kush, PhD, President and CEO, CDISC CDISC 2015 1 CDISC Healthcare Link Goal: Optimize
PharmaSUG2010 HW06. Insights into ADaM. Matthew Becker, PharmaNet, Cary, NC, United States
PharmaSUG2010 HW06 Insights into ADaM Matthew Becker, PharmaNet, Cary, NC, United States ABSTRACT ADaM (Analysis Dataset Model) is meant to describe the data attributes such as structure, content, and
Qualification Process for Standard Scripts in the Open Source Repository with Cloud Services
PharmaSUG 2015 - Paper AD10 Qualification Process for Standard Scripts in the Open Source Repository with Cloud Services Hanming Tu, Accenture, Berwyn, PA, USA Dante Di Tommaso, Roche, Basel, Switzerland
Healthcare Data: Secondary Use through Interoperability
Healthcare Data: Secondary Use through Interoperability Floyd Eisenberg MD MPH July 18, 2007 NCVHS Agenda Policies, Enablers, Restrictions Date Re-Use Landscape Sources of Data for Quality Measurement,
Development of CDISC Tuberculosis Data Standards
Development of CDISC Tuberculosis Data Standards Michael Fiola Senior Director / Quintiles The presenters have disclosed that they have no proprietary or financial interests in the topics covered in this
Optimizing Safety Surveillance During Clinical Trials Using Data Visualization Tools
Optimizing Safety Surveillance During Clinical Trials Using Data Visualization Tools Laura McKain, M.D., Medical Director, Pharmacovigilance; Tammy Jackson, Director, Preclarus Development, Clinical Innovation;
Clinical Data Management Overview
The 2 nd Clinical Data Management Training Clinical Data Management Overview Andrew Taylor ( 安 泰 乐 ), M.S. Head of Clinical Data Management August 30, 2010 Learning Objectives Overview of Process Related
ADaM Implications from the CDER Data Standards Common Issues and SDTM Amendment 1 Documents Sandra Minjoe, Octagon Research Solutions, Wayne, PA
ABSTRACT: ADaM Implications from the CDER Data Standards Common Issues and SDTM Amendment 1 Documents Sandra Minjoe, Octagon Research Solutions, Wayne, PA Over the past few years, the United States Food
Application of Clinical Trial Certificate of Chinese Medicines in Hong Kong
Application of Clinical Trial Certificate of Chinese Medicines in Hong Kong D R. K F C H U N G D E P A R T M E N T O F P S Y C H I A T R Y U N I V E R S I T Y O F H O N G K O N G ( S E P T 2 0 1 4 ) Evidence-based
Implementing the CDISC standards into an existing CDMS
Implementing the CDISC standards into an existing CDMS Presented by Ueng-Cheng Yang ([email protected]) Institute of Biomedical Informatics National Yang-Ming University 1 TCT is a resource center to support
PEER REVIEW HISTORY ARTICLE DETAILS
PEER REVIEW HISTORY BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (http://bmjopen.bmj.com/site/about/resources/checklist.pdf)
How To Analyze Data From A Patient Record
EHR Minimum Data Set Mark Roche, MD, MSMI Senior Health IT Advisor to the Office of the National Coordinator (ONC) 1 Agenda Current state DE Analysis background DE Analysis results Next Steps 2 Current
Establishment Registration SPL Technical Errors Training ebook
Technical Errors Training ebook Interpretations & s for Technical Errors in Establishment Registration SPL Documents Submitted to FDA Version 1.0 Purpose: This SPL training ebook is to be utilized by SPL
LUNG CANCER CLINICAL TRIALS
UNDERSTANDING LUNG CANCER CLINICAL TRIALS 1-800-298-2436 LungCancerAlliance.org A GUIDE FOR THE PATIENT 1 TABLE OF CONTENTS INTRODUCTION TO CLINICAL TRIALS What Is a Clinical Trial?...4 Types of Clinical
A Brief Introduc/on to CDISC SDTM and Data Mapping
A Brief Introduc/on to CDISC SDTM and Data Mapping Agenda Flow of Clinical Trials Data The Problem Introducing CDISC Understanding SDTM Concepts of Data Mapping References 5/3/10 2 Flow of Clinical Trials
Lessons on the Metadata Approach. Dave Iberson- Hurst 9 th April 2014 CDISC Euro Interchange 2014
1 Lessons on the Metadata Approach Dave Iberson- Hurst 9 th April 2014 CDISC Euro Interchange 2014 2 Experience Human beings, who are almost unique in having the ability to learn from the experience of
Janus Clinical Trials Repository (CTR) An Update
Janus Clinical Trials Repository (CTR) An Update Armando Oliva, M.D. Associate Director for Informatics CDER Office of Computational Science U.S. Food and Drug Administration 2015-03-16 The views expressed
Electronic Submission of Regulatory Information, and Creating an Electronic Platform for Enhanced Information Management
Written Notice of Participation by the Clinical Data Interchange Standards Consortium (CDISC) and Written Statement for Discussion Topics to be Addressed In the FDA Public Hearing: Electronic Submission
Cancer Clinical Trials: In-Depth Information
Cancer Clinical Trials: In-Depth Information The Drug Development and Approval Process 1. Early research and preclinical testing 2. IND application filed with FDA 3. Clinical trials (phases 1, 2, and 3)
University of Hawai i Human Studies Program. Guidelines for Developing a Clinical Research Protocol
University of Hawai i Human Studies Program Guidelines for Developing a Clinical Research Protocol Following are guidelines for writing a clinical research protocol for submission to the University of
How to Create Variables Related to Age Joyce Gui and Shaoan Yu Merck & Company, Rahway, NJ
Paper SBC 131 How to Create Variables Related to Age Joyce Gui and Shaoan Yu Merck & Company, Rahway, NJ ABSTRACT A derived variable not explicitly included in a domain model is permissible to be used
ICD-10 Transition Overview
ICD-10 Transition Overview Donna Pickett, MPH, RHIA OSELS/National Center for Health Statistics Centers for Disease Control and Prevention U.S. Department of Health and Human Services Centers for Disease
Implementing CDASH Standards Into Data Collection and Database Design. Robert Stemplinger ICON Clinical Research
Implementing CDASH Standards Into Data Collection and Database Design Robert Stemplinger ICON Clinical Research 1 Agenda Reasons for Using CDASH Project Outline Implementation Discussion of Results Reasons
Providing Regulatory Submissions In Electronic Format Standardized Study Data
Providing Regulatory Submissions In Electronic Format Standardized Study Data Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
Participating in Alzheimer s Disease Clinical Trials and Studies
Participating in Alzheimer s Disease Clinical Trials and Studies FACT SHEET When Margaret was diagnosed with earlystage Alzheimer s disease at age 68, she wanted to do everything possible to combat the
SDTM, ADaM and define.xml with OpenCDISC Matt Becker, PharmaNet/i3, Cary, NC
PharmaSUG 2012 - Paper HW07 SDTM, ADaM and define.xml with OpenCDISC Matt Becker, PharmaNet/i3, Cary, NC ABSTRACT Standards are an ongoing focus of the health care and life science industry. Common terms
4. Executive Summary of Part 1 FDA Overview of Current Environment
Public Meeting Regulatory New Drug Review: Solutions for Study Data Exchange Standards 1. Background Meeting Summary Food and Drug Administration White Oak, MD November 5, 2012 10am 4pm On November 5,
Subject: No. Page PROTOCOL AND CASE REPORT FORM DEVELOPMENT AND REVIEW Standard Operating Procedure
703 1 of 11 POLICY The Beaumont Research Coordinating Center (BRCC) will provide advice to clinical trial investigators on protocol development, content and format. Upon request, the BRCC will review a
Priority Program Translational Oncology Applicants' Guidelines
Stiftung Deutsche Krebshilfe Dr. h.c. Fritz Pleitgen Präsident Spendenkonto Kreissparkasse Köln IBAN DE65 3705 0299 0000 9191 91 BIC COKSDE33XXX Priority Program Translational Oncology Applicants' Guidelines
TAKING PART IN CANCER TREATMENT RESEARCH STUDIES
For more infomation about Cancer Clinical Trials at Upstate Cancer Center please call Upstate Connect 1.800.464.8668 TAKING PART IN CANCER TREATMENT RESEARCH STUDIES Information provided by: National Cancer
ICH guideline E2B (R3) - questions and answers
25 August 2015 EMA/CHMP/ICH/3943/2003 Committee for Human Medicinal Products Step 5 Transmission to CHMP for adoption December 2014 Release for information January 2015 30 Churchill Place Canary Wharf
A Greater Understanding. A Practical Guide to Clinical Trials
A Greater Understanding A Practical Guide to Clinical Trials Solving Insurance and Healthcare AccessProblems I since 1996 A Greater Understanding Patient Advocate Foundation MISSION STATEMENT Patient Advocate
A guide for the patient
Understanding series LUNG CANCER CLINICAL TRIALS 1-800-298-2436 LungCancerAlliance.org A guide for the patient TABLE OF CONTENTS The Basics What is a Clinical Trial?...3 Types of Clinical Trials... 3 Phases
Joint Position on the Disclosure of Clinical Trial Information via Clinical Trial Registries and Databases 1 Updated November 10, 2009
Joint Position on the Disclosure of Clinical Trial Information via Clinical Trial Registries and Databases 1 Updated November 10, 2009 The innovative pharmaceutical industry 2 is committed to the transparency
Analysis Data Model: Version 2.0
1 2 Analysis Data Model: Version 2.0 Prepared by the CDISC Analysis Dataset Modeling Team (ADaM) Notes to Readers This Model incorporates aspects of the previous General Considerations document version
Data modelling methods in clinical trials: Experiences from the CTMND project (ctmnd.org)
Data modelling methods in clinical trials: Experiences from the CTMND project (ctmnd.org) Athanasios Anastasiou, Emmanuel Ifeachor, John Zajicek & the CTMND Consortium University of Plymouth Peninsula
The Development of the Clinical Trial Ontology to standardize dissemination of clinical trial data. Ravi Shankar
The Development of the Clinical Trial Ontology to standardize dissemination of clinical trial data Ravi Shankar Open access to clinical trials data advances open science Broad open access to entire clinical
EU Clinical Trials Register
EU Clinical Trials Register Disclaimer: The explanations are provided for the benefit of public users of the system and to enhance general understanding of terms used. They are not intended as the regulatory
QualityView - a program database and validation documentation tool
Paper RC03 QualityView - a program database and validation documentation tool Peter Gerber, Accovion GmbH, Frankfurt, Germany Michael Ludwig, Accovion GmbH, Frankfurt, Germany ABSTRACT During the analysis
National Cancer Institute
National Cancer Institute Taking Part in Cancer Treatment Research Studies U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Taking Part in Cancer Treatment Research Studies If
Training/Internship Brochure Advanced Clinical SAS Programming Full Time 6 months Program
Training/Internship Brochure Advanced Clinical SAS Programming Full Time 6 months Program Domain Clinical Data Sciences Private Limited 8-2-611/1/2, Road No 11, Banjara Hills, Hyderabad Andhra Pradesh
Briefing on ehr Content Hong Kong Clinical Terminology Table (HKCTT) By Maggie LAU Health Informatician, ehriso
Briefing on ehr Content Hong Kong Clinical Terminology Table (HKCTT) By Maggie LAU Health Informatician, ehriso Agenda Background Application Adoption Management RecognisedTerminologies in ehr Registered
Understanding Clinical Trials
Understanding Clinical Trials The UK Clinical Research Collaboration (UKCRC) is a partnership of organisations working to establish the UK as a world leader in clinical research, by harnessing the power
Guidance for Industry
Reprinted from FDA s website by EAS Consulting Group, LLC Guidance for Industry Providing Regulatory Submissions in Electronic Format Standardized Study Data DRAFT GUIDANCE This guidance document is being
Therapeutic Area Data Standards User Guide for Multiple Sclerosis Version 1.0
Therapeutic Area Data Standards User Guide for Multiple Sclerosis Version 1.0 Prepared by the Multiple Sclerosis Outcome Assessments Consortium and the CFAST Multiple Sclerosis Development Team Notes to
Standard Operating Procedure. Clinical Trial Authorisation
Standard Operating Procedure for Clinical Trial Authorization Scope This SOP has been written to describe the procedure undertaken to apply for Clinical Trial Authorisation from Competent Authorities in
Analysis Data Model (ADaM) Implementation Guide
Analysis Data Model (ADaM) Implementation Guide Prepared by the CDISC Analysis Data Model Team Notes to Readers This Implementation Guide is Version 1.0 (V1.0) and corresponds to Version 2.1 of the CDISC
International HL7 Interoperability Conference - IHIC 2010
International HL7 Interoperability Conference - IHIC 2010 National ehealth Initiatives: Global Health Information Technology Standards Serving Local Needs Building Interoperability across many localities
How to search the EU Clinical Trials Register
28 April 2014 Information and Communications Technology Contents Contents... 1 1. Searching the EU Clinical Trials Register... 1 1.1. Basic search... 2 1.2. Search for multiple words (AND operator)...
A Standard Computable Clinical Trial Protocol: The Role of the BRIDG Model
CLINICAL RESEARCH STANDARDS 383 Cara Willoughby, MS Eli Lilly and Company, Indianapolis, Indiana Doug Fridsma, MD, PhD University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania Lisa Chatterjee,
Implementation of SDTM in a pharma company with complete outsourcing strategy. Annamaria Muraro Helsinn Healthcare Lugano, Switzerland
Italian-Speaking CDISC User Group 2008 Implementation of SDTM in a pharma company with complete outsourcing strategy Annamaria Muraro Helsinn Healthcare Lugano, Switzerland Background Full outsourcing
New features in SDTM-ETL v.1.2 1 SDTM-ETL TM. New Features in version 1.2
New features in SDTM-ETL v.1.2 1 SDTM-ETL TM New Features in version 1.2 This document describes the new features in version 1.2 of the SDTM-ETL TM software. It can be used in addition to the STDM-ETL
The CDISC/FDA Integrated Data Pilot: A Case. Support an Integrated Review
The CDISC/FDA Integrated Data Pilot: A Case Studyin Implementing CDISC Standards to Support an Integrated Review d Wise Technologies Chris Decker Life Sciences Director Overview Pilot Mission and Goals
PharmaSUG 2015 - Paper DS07
PharmaSUG 2015 - Paper DS07 The Best Practices of CDISC Validation Checks: Past, Present, and Future Shelley Dunn, d-wise, Morrisville, NC Ed Lombardi, Agility Clinical, Carlsbad, CA ABSTRACT The CDISC
ehr Sharable Data - Prescribing Record Validation Rule Code Table Data requirement (Certified Level 1)
ehr Sharable - Form Entity Name Definition Type (code) Type (description ) Validation Rule Code Table Prescription datetime Datetime when the prescription was made TS Time stamp NA M M 6/12/2010 6/12/2010
PG Certificate / PG Diploma / MSc in Clinical Pharmacy
PG Certificate / PG Diploma / MSc in Clinical Pharmacy Programme Information September 2014 Entry School of Pharmacy Queen s University Belfast Queen s University Belfast - Clinical Pharmacy programme
What is your level of coding experience?
The TrustHCS Academy is dedicated to growing new coders to enter the field of medical records coding while also increasing the ICD-10 skills of seasoned coding professionals. A unique combination of on-line
Entering a Clinical Trial
Entering a Clinical Trial Is It Right for You? Paula Chandoha, Chandoha Productions About This Program THIS AUDIOVISUAL PROGRAM AND BOOKLET WERE produced by Dana-Farber Cancer Institute in collaboration
PROTOCOL SYNOPSIS Evaluation of long-term opioid efficacy for chronic pain
P a g e 1 PROTOCOL SYNOPSIS Evaluation of long-term opioid efficacy for chronic pain Clinical Phase 4 Study Centers Study Period 25 U.S. sites identified and reviewed by the Steering Committee and Contract
PCORI Methodology Standards: Academic Curriculum. 2016 Patient-Centered Outcomes Research Institute. All Rights Reserved.
PCORI Methodology Standards: Academic Curriculum 2016 Patient-Centered Outcomes Research Institute. All Rights Reserved. Module 9: Putting it All Together: Appraising a Systematic Review Category 11: Systematic
Measure #41: Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older National Quality Strategy Domain: Effective Clinical Care
Measure #41: Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY
Metadata and ADaM. www.cytel.com
Metadata and ADaM 1 Disclaimer Any views or opinions presented in this presentation are solely those of the author and do not necessarily represent those of the company. 2 Agenda Introduction of ADaM Metadata
CDER/CBER s Top 7 CDISC Standards Issues
CDER/CBER s Top 7 CDISC Standards Issues Dhananjay Chhatre, MS, RAC edata Management Solutions Team Office of Business Informatics CDER, U.S. FDA Amy Malla Review Management CBER, U.S. FDA Background ~
Investigational Drugs: Investigational Drugs and Biologics
: I. PURPOSE The purpose of this policy is to establish procedures for the proper control, storage, use and handling of investigational drugs and biologics to ensure that adequate safeguards are in place
Guidance for Industry
Guidance for Industry E2F Development Safety Update Report U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics
